1.Implementation of point-of-care platforms for rapid detection of porcine circovirus type 2
Chiao-Hsu KE ; Mao-Yuan DU ; Wang-Ju HSIEH ; Chiu-Chiao LIN ; James Mingjuh TING ; Ming-Tang CHIOU ; Chao-Nan LIN
Journal of Veterinary Science 2024;25(2):e28-
Background:
Porcine circovirus type 2 (PCV2) infection is ubiquitous around the world.Diagnosis of the porcine circovirus-associated disease requires clinic-pathological elements together with the quantification of viral loads. Furthermore, given pig farms in regions lacking access to sufficient laboratory equipment, developing diagnostic devices with high accuracy, accessibility, and affordability is a necessity.
Objectives:
This study aims to investigate two newly developed diagnostic tools that may satisfy these criteria.
Methods:
We collected 250 specimens, including 170 PCV2-positive and 80 PCV2-negative samples. The standard diagnosis and cycle threshold (Ct) values were determined by quantitative polymerase chain reaction (qPCR). Then, two point-of-care (POC) diagnostic platforms, convective polymerase chain reaction (cPCR, qualitative assay: positive or negative results are shown) and EZtargex (quantitative assay: Ct values are shown), were examined and analyzed.
Results:
The sensitivity and specificity of cPCR were 88.23% and 100%, respectively; the sensitivity and specificity of EZtargex were 87.65% and 100%, respectively. These assays also showed excellent concordance compared with the qPCR assay (κ = 0.828 for cPCR and κ = 0.820 for EZtargex). The statistical analysis showed a great diagnostic power of the EZtargex assay to discriminate between samples with different levels of positivity.
Conclusions
The two point-of-care diagnostic platforms are accurate, rapid, convenient and require little training for PCV2 diagnosis. These POC platforms can discriminate viral loads to predict the clinical status of the animals. The current study provided evidence that these diagnostics were applicable with high sensitivity and specificity in the diagnosis of PCV2 infection in the field.
2.Clinical guideline on first aid for blast injury of the chest (2022 edition)
Zhiming SONG ; Jianming CHEN ; Jing ZHONG ; Yunfeng YI ; Lianyang ZHANG ; Jianxin JIANG ; Mao ZHANG ; Yang LI ; Guodong LIU ; Dingyuan DU ; Jiaxin MIN ; Xu WU ; Shuogui XU ; Anqiang ZHANG ; Yaoli WANG ; Hao TANG ; Qingshan GUO ; Yigang YU ; Xiangjun BAI ; Gang HUANG ; Zhiguang YANG ; Yunping ZHAO ; Sheng LIU ; Lijie TAN ; Lei TONG ; Xiaoli YUAN ; Yanmei ZHAO ; Haojun FAN
Chinese Journal of Trauma 2022;38(1):11-22
Blast injury of the chest injury is the most common wound in modern war trauma and terrorist attacks, and is also the most fatal type of whole body explosion injury. Most patients with severe blast injury of the chest die in the early stage before hospitalization or during transportation, so first aid is critically important. At present, there exist widespread problems such as non-standard treatment and large difference in curative effect, while there lacks clinical treatment standards for blast injury of the chest. According to the principles of scientificity, practicality and advancement, the Trauma Society of Chinese Medical Association has formulated the guidance of classification, pre-hospital first aid, in-hospital treatment and major injury management strategies for blast injury of the chest, aiming to provide reference for clinical diagnosis and treatment.
3.Research progress on building of disease control and prevention system of the international experience
Minjie ZHAO ; Ayan MAO ; Shasha YUAN ; Kun WANG ; Pei DONG ; Shuai DU ; Yueli MENG ; Wuqi QIU
Chinese Journal of Preventive Medicine 2021;55(10):1263-1269
Through literature search in regular database and official websites of relevant countries, this paper combs and summarizes the main characteristics of disease prevention and control systems in five countries, the United States, Germany, South Korea, Australia and Japan, and the European Union at key levels including legal construction, organizational structure, financing, personnel construction and international cooperation, in order to provide decision support for the construction of disease prevention and control system in China in the future.
4.Research progress on building of disease control and prevention system of the international experience
Minjie ZHAO ; Ayan MAO ; Shasha YUAN ; Kun WANG ; Pei DONG ; Shuai DU ; Yueli MENG ; Wuqi QIU
Chinese Journal of Preventive Medicine 2021;55(10):1263-1269
Through literature search in regular database and official websites of relevant countries, this paper combs and summarizes the main characteristics of disease prevention and control systems in five countries, the United States, Germany, South Korea, Australia and Japan, and the European Union at key levels including legal construction, organizational structure, financing, personnel construction and international cooperation, in order to provide decision support for the construction of disease prevention and control system in China in the future.
5.Common susceptibility loci in both systemic sclerosis and localized scleroderma identified using genetic analysis.
Yun LI ; Wen-Jun WANG ; Wei-Wei CHEN ; Xue FAN ; Lu CAO ; Ze-Yu XING ; Qi ZHEN ; Qiong-Qiong XU ; Chen-Yu ZHU ; Hui-Yao GE ; Dian CHEN ; Rui-Xue ZHANG ; Chang SHU ; Wei DU ; Shi-Rui CHEN ; Xie YUAN ; Hui ZHANG ; Xia HU ; Xu-Ming MAO ; Qiu-Ning SUN
Chinese Medical Journal 2020;133(19):2370-2372
6.Modulation effect of Acanthopanax senticosus polysaccharides through inflammatory cytokines in protecting immunological liver-injured mice.
Na ZHANG ; Liang-You ZHAO ; Di MAO ; Zhao-Yuan DU ; Xiao-Juan ZHANG ; Xu-Nan ZHAI ; Bai-Song AN ; Shu-Min LIU
China Journal of Chinese Materia Medica 2019;44(14):2947-2952
The aim of this paper was to discuss the protective effect and mechanism of Acanthopanax senticosus polysaccharides( ASPs) on immunological liver injury caused by conanavalin A( Con A). BALB/c mice were randomly divided into seven groups: control group,model group( Con A),low-,medium-,and high-dose( 36. 25,72. 5,145 mg·kg~(-1)) ASPs groups,bifendate( 200 mg·kg~(-1),positive drug) group and pyrrolidinedithiocarbamate( PDTC,NF-κB inhibitor,200 mg·kg~(-1)) group. ASPs groups and bifendate group were given with corresponding drugs by ig administration once daily for 7 d. Control group,model group and PDTC group were given with normal saline by ig administration once daily for 7 d. After the last ig administration,PDTC was given in DTC group by iv administration( 200 mg·kg~(-1)); 0. 5 h after that,Con A( 20 mg·kg~(-1)) was injected via the tail vein to induce immunological liver injury in all the mice except normal control group. The mice were killed 8 h later and their liver tissues were collected for histopathological examination. The contents of nitric oxide( NO),superoxide dismutase( SOD),malondialdehyde( MDA),reduced glutathione( GSHPX),interleukin( IL-1β) and tumor necrosis factor( TNF-α) in liver tissues were detected by kit assay. Western blot method was used to detect TNF-α,intercellular cell adhesion molecule-1( ICAM-1),inducible nitric oxide synthase( i NOS) and nuclear factor( NF-κB) protein expression in liver tissues. As compared with model group,ASPs not only could reduce the activity of MDA,NO,IL-1β and TNF-α,but also increase the content of GSH-PX and SOD; at the same time,the protein expression levels of TNF-α,ICAM-1,i NOS and NF-κB were reduced in liver tissues; in addition,inflammatory cell infiltration was alleviated,hepatocyte cytoplasm was loose and swollen,and nuclear condensation and staining were improved. ASPs has a protective effect on immunological liver injury,and the mechanism may be associated with regulating secretion of inflammatory cytokines and the expression of adhesion factor through NF-κB signaling pathway.
Animals
;
Chemical and Drug Induced Liver Injury
;
drug therapy
;
Cytokines
;
metabolism
;
Eleutherococcus
;
chemistry
;
Liver
;
drug effects
;
Mice
;
Mice, Inbred BALB C
;
NF-kappa B
;
metabolism
;
Peptides, Cyclic
;
Polysaccharides
;
pharmacology
;
Random Allocation
;
Signal Transduction
7.Current situation and consideration of patent protection in classical representative famous prescriptions in China.
Shuai-Mei ZHAO ; Jiang-Xiu SONG ; Mao-Bo DU ; Ya-Nan YUAN
China Journal of Chinese Materia Medica 2019;44(18):4067-4071
Classical Representative Famous Prescription is the valuable cultural heritage of Chinese medicine. In November 2018,the State Council issued the " Intensive Implementation of the National Intellectual Property Strategy in 2018 to Accelerate the Construction of IP Strong Country",explicitly proposing to strengthen the intellectual property protection of Classical Representative Famous Prescription.How about the current situation of intellectual property protection of lassical Representative Famous Prescription in China? We selected Liuwei Dihuang Pills,Shengmai Powder and Guizhi Fuling Pills( three representative drugs on market) from Chinese Pharmacopoeia2015 Volume I issued by Chinese Pharmacopoeia Commission to analyze their patent layout,reflecting its status quo of patent protection as follows: first,in recent years,the number of related patent applications for Classical Representative Famous Prescriptions has declined,which was positively correlated with the drug registration and approval policies in recent years,but the policy dividend has not been reflected in the patent application,which may be related to the long period of pharmaceutical R&D; secondly,the patent applicant in the field of Chinese medicine is mainly based on individuals,but the applicant of Classical Representative Famous Prescription is mainly of enterprises,and in addition,the company applicants have the highest authorization rate; thirdly,the main technologies are to improve preparation method and the dosage form in the research and development of Classical Representative Famous Prescription,but these two types of authorized patents have much difficulty in further application on the market. Therefore,the innovative entities shall look for a new breakthrough in secondary development and utilization of Classical Representative Famous Prescriptions.
China
;
Drug Combinations
;
Drugs, Chinese Herbal
;
Medicine, Chinese Traditional
;
Patents as Topic
8.The Changes of HIF-1α and VEGF-A in Myocardial Tissue of Rats with Arrhyth-mias
Yuan ZHANG ; Zhipeng CAO ; Ruiming MAO ; Zhongbo DU ; Li MI ; Xinyi LUO ; Meihui TIAN ; Baoli ZHU
Journal of Forensic Medicine 2017;33(3):225-231
Objective T o observe the expression changes of hypoxia inducible factor-1α (H IF-1α) and vascular endothelial grow th factor-A (V E G F-A ) in rats w ith arrhythm ias, and to explore the differences of the expression pattern in the tw o indicators of acute m yocardial ischem ia caused by arrhythm ias and coronary insufficiency. Methods T he arrhythm ia w as induced by C aC l2, and the expression changes of H IF-1α and V E G F-A w ere detected by im m unohistochem istry, W estern blotting and real-tim e PC R w ithin 6 h after the arrhythm ia in rats. Results T he expression of H IF-1α and V E G F-A show ed diffuse in the m yocardial tissue of rats died from arrhythm ias. B oth of them increased in the early arrhythm ia, then decreased. E xtensive m yocardial ischem ia happened at the beginning of arrhythm ia occurrence and its range didn't expand w ith tim e. Conclusion T he expressions of H IF-1α and V E G F-A in m yocardium of the rats w ith arrhythm ia can provide evidence for the differential diagnosis of acute m yocardial is-chem ia caused by fatal arrhythm ia and coronary insufficiency.
9.Expenditure and financial burden for the diagnosis and treatment of colorectal cancer in China: a hospital-based, multicenter,cross-sectional survey
Huang HUI-YAO ; Shi JU-FANG ; Guo LAN-WEI ; Bai YA-NA ; Liao XIAN-ZHEN ; Liu GUO-XIANG ; Mao A-YAN ; Ren JIAN-SONG ; Sun XIAO-JIE ; Zhu XIN-YU ; Wang LE ; Song BING-BING ; Du LING-BIN ; Zhu LIN ; Gong JI-YONG ; Zhou QI ; Liu YU-QIN ; Cao RONG ; Mai LING ; Lan LI ; Sun XIAO-HUA ; Ren YING ; Zhou JIN-YI ; Wang YUAN-ZHENG ; Qi XIAO ; Lou PEI-AN ; Shi DIAN ; Li NI ; Zhang KAI ; He JIE ; Dai MIN
Chinese Journal of Cancer 2017;36(8):352-366
Background:The increasing prevalence of colorectal cancer (CRC) in China and the paucity of information about relevant expenditure highlight the necessity of better understanding the financial burden and effect of CRC diagnosis and treatment.We performed a survey to quantify the direct medical and non-medical expenditure as well as the resulting financial burden of CRC patients in China.Methods:We conducted a multicenter,cross-sectional survey in 37 tertiary hospitals in 13 provinces across China between 2012 and 2014.Each enrolled patient was interviewed using a structured questionnaire.All expenditure data were inflated to the 2014 Chinese Yuan (CNY;1 CNY =0.163 USD).We quantified the overall expenditure and financial burden and by subgroup (hospital type,age at diagnosis,sex,education,occupation,insurance type,household income,clinical stage,pathologic type,and therapeutic regimen).We then performed generalized linear modeling to determine the factors associated with overall expenditure.Results:A total of 2356 patients with a mean age of 57.4 years were included,57.1% of whom were men;13.9% of patients had stage Ⅰ cancer;and the average previous-year household income was 54,525 CNY.The overall average direct expenditure per patient was estimated to be 67,408 CNY,and the expenditures for stage Ⅰ,Ⅱ,Ⅲll,and Ⅳ disease were 56,099 CNY,59,952 CNY,67,292 CNY,and 82,729 CNY,respectively.Non-medical expenditure accounted for 8.3% of the overall expenditure.The 1-year out-of-pocket expenditure of a newly diagnosed patient was 32,649 CNY,which accounted for 59.9% of their previous-year household income and caused 75.0% of families to suffer an unmanageable financial burden.Univariate analysis showed that financial burden and overall expenditure differed in almost all subgroups (P < 0.05),except for sex.Multivariate analysis showed that patients who were treated in specialized hospitals and those who were diagnosed with adenocarcinoma or diagnosed at a later stage were likely to spend more,whereas those with a lower household income and those who underwent surgery spent less (all P < 0.05).Conclusions:For patients in China,direct expenditure for the diagnosis and treatment of CRC seemed catastrophic,and non-medical expenditure was non-ignorable.The financial burden varied among subgroups,especially among patients with different clinical stages of disease,which suggests that,in China,CRC screening might be cost-effective.
10.The Changes of HIF-1α and VEGF-A in Myocardial Tissue of Rats with Arrhythmias.
Yuan ZHANG ; Zhi Peng CAO ; Rui Ming MAO ; Zhong Bo DU ; Li MI ; Xin Yi LUO ; Mei Hui TIAN ; Bao Li ZHU
Journal of Forensic Medicine 2017;33(3):225-231
OBJECTIVES:
To observe the expression changes of hypoxia inducible factor-1α(HIF-1α) and vascular endothelial growth factor-A (VEGF-A) in rats with arrhythmias, and to explore the differences of the expression pattern in the two indicators of acute myocardial ischemia caused by arrhythmias and coronary insufficiency.
METHODS:
The arrhythmia was induced by CaCl₂, and the expression changes of HIF-1α and VEGF-A were detected by immunohistochemistry, Western blotting and real-time PCR within 6 h after the arrhythmia in rats.
RESULTS:
The expression of HIF-1α and VEGF-A showed diffuse in the myocardial tissue of rats died from arrhythmias. Both of them increased in the early arrhythmia, then decreased. Extensive myocardial ischemia happened at the beginning of arrhythmia occurrence and its range didn't expand with time.
CONCLUSIONS
The expressions of HIF-1α and VEGF-A in myocardium of the rats with arrhythmia can provide evidence for the differential diagnosis of acute myocardial ischemia caused by fatal arrhythmia and coronary insufficiency.
Animals
;
Arrhythmias, Cardiac/metabolism*
;
Hypoxia-Inducible Factor 1, alpha Subunit/metabolism*
;
Myocardial Ischemia/metabolism*
;
Myocardium/metabolism*
;
Rats
;
Vascular Endothelial Growth Factor A/metabolism*

Result Analysis
Print
Save
E-mail